文献速递炎症性肠病

古塞奇尤单抗治疗中重度活动性溃疡性结肠炎:QUASAR 2b期诱导研究

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
PubMed 文献 · Gastroenterology · 2023-09-01

QUASAR 2b期诱导研究将中重度活动性溃疡性结肠炎患者按1:1:1随机分配至静脉注射古塞奇尤单抗200 mg、400 mg或安慰剂组,于第0/4/8周给药。第12周临床应答率古塞奇尤单抗200 mg组为61.4%、400 mg组为60.7%,均高于安慰剂组的27.6%(两项P < .001)。古塞奇尤单抗安全性良好,两个剂量组疗效与安全性相似。

要点

  • 第12周临床应答率:古塞奇尤单抗200 mg组61.4%、400 mg组60.7%,均高于安慰剂组27.6%(两项P < .001)。
  • 古塞奇尤单抗组在所有主要次要终点(临床缓解、症状缓解、内镜改善、组织-内镜黏膜改善、内镜正常化)的比例均高于安慰剂组。
  • 古塞奇尤单抗安全性与安慰剂相似,两个剂量组疗效与安全性相似。

核心结论

  • 静脉注射古塞奇尤单抗诱导治疗对中重度活动性溃疡性结肠炎患者有效,且优于安慰剂。
  • 古塞奇尤单抗安全性良好,两个剂量组疗效与安全性相似。

研究设计与样本

  • 双盲、安慰剂对照、剂量探索的诱导研究。
  • 患者按1:1:1随机接受静脉注射古塞奇尤单抗200 mg、400 mg或安慰剂,于第0/4/8周给药。
  • 主要分析人群为基线改良Mayo评分≥5且≤9的患者:静脉注射古塞奇尤单抗200 mg组n = 101,400 mg组n = 107,安慰剂组n = 105。
  • 第12周临床无应答者进入非对照研究期:古塞奇尤单抗组接受皮下注射古塞奇尤单抗200 mg,安慰剂组接受静脉注射古塞奇尤单抗200 mg,于第12/16/20周给药。

主要发现

  • 第12周临床应答率:古塞奇尤单抗200 mg组61.4%、400 mg组60.7%,均高于安慰剂组27.6%(两项P < .001)。
  • 第12周古塞奇尤单抗组在所有主要次要终点(临床缓解、症状缓解、内镜改善、组织-内镜黏膜改善、内镜正常化)的比例均高于安慰剂组。
  • 古塞奇尤单抗第12周临床无应答者中,200 mg组54.3%、400 mg组50.0%在第24周达到临床应答。
  • 古塞奇尤单抗与安慰剂组安全性相似。

关键数值与推荐

  • 主要终点为第12周临床应答:较基线改良Mayo评分降低≥30%且≥2分,直肠出血亚评分降低≥1分或亚评分为0/1。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The QUASAR Phase 2b Induction Study evaluated the efficacy and safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients with moderately to severely active ulcerative colitis (UC) with prior inadequate response and/or intolerance to corticosteroids, immunosuppressants, and/or advanced therapy. METHODS: In this double-blind, placebo-controlled, dose-ranging, induction study, patients were randomized (1:1:1) to receive intravenous guselkumab 200 or 400 mg or placebo at weeks 0/4/8. The primary endpoint was clinical response (compared with baseline, modified Mayo score decrease ≥30% and ≥2 points, rectal bleeding subscore ≥1-point decrease or subscore of 0/1) at week 12. Guselkumab and placebo week-12 clinical nonresponders received subcutaneous or intravenous guselkumab 200 mg, respectively, at weeks 12/16/20 (uncontrolled study period). RESULTS: The primary analysis population included patients with baseline modified Mayo scores ≥5 and ≤9 (intravenous guselkumab 200 mg, n = 101; 400 mg, n = 107; placebo, n = 105). Week-12 clinical response percentage was greater with guselkumab 200 mg (61.4%) and 400 mg (60.7%) vs placebo (27.6%; both P < .001). Greater proportions of guselkumab-treated vs placebo-treated patients achieved all major secondary endpoints (clinical remission, symptomatic remission, endoscopic improvement, histo-endoscopic mucosal improvement, and endoscopic normalization) at week 12. Among guselkumab week-12 clinical nonresponders, 54.3% and 50.0% of patients in the 200- and 400-mg groups, respectively, achieved clinical response at week 24. Safety was similar among guselkumab and placebo groups. CONCLUSIONS: Guselkumab intravenous induction was effective vs placebo in patients with moderately to severely active UC. Guselkumab was safe, and efficacy and safety were similar between guselkumab dose groups. CLINICALTRIALS: gov number: NCT04033445.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Peyrin-Biroulet L, Allegretti JR, Rubin DT, et al. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Gastroenterology. 2023. PMID: 37659673. doi:10.1053/j.gastro.2023.08.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。